We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Groundbreaking RNA Extraction-Free qSanger-COVID-19 Assay Secures FDA EUA

By LabMedica International staff writers
Posted on 08 Sep 2020
Print article
Illustration
Illustration
A groundbreaking SARS-CoV-2 diagnostic test which eliminates the costly and time-consuming step of RNA extraction has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA).

Most other molecular assays rely on RNA extraction and qRT-PCR. However, the qSanger-COVID-19 assay from BillionToOne, Inc. (Palo Alto, CA, USA) uses a different set of instruments and chemicals from existing tests, enabling labs to unlock a new, unused capacity for the detection of SARS-CoV-2. The test is easily adaptable with minimum training at any laboratories with Sanger Sequencers, which most major clinical laboratories have readily available.

BillionToOne developed the test based on its patent-pending qSanger technology. The test adopts the technology behind the Human Genome Project - Sanger sequencing - for the reliable detection of viral RNA. The approach vastly increases testing capacity as a single sequencer can process an average of 4,000 tests per day - 20 times more than qRT-PCR instruments. BillionToOne's testing method also removes the costly, time-consuming process of RNA extraction, making its tests more cost-effective, highly scalable, and requiring less manpower to conduct. The removal of the RNA extraction process also removes a critical bottleneck in expanding testing capacity across the US. BillionToOne completed the development of its COVID-19 assay kits by utilizing Swift Biosciences' custom manufacturing and distribution expertise and both the companies are currently working together with multiple clinical laboratories in the US and around the world to help them adopt the testing protocol.

"A critical element of combating COVID-19 and enabling communities and economies to reopen is our ability to deliver widespread, cost-effective diagnostic testing across the United States and globally," said Dr. Oguzhan Atay, CEO of BillionToOne. "With the emergency use authorization of our RNA extraction-free tests, we can now roll out the test in US laboratories in addition to international labs. We're proud to be on the front lines of the effort to confront the coronavirus pandemic and have now unlocked a cost-effective, scalable way to expand testing in all major laboratories."

Related Links:
BillionToOne, Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.